Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)


0.00 (0.00%)

Market Cap$8,938,628,295

02/24/17  4:00 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics to Present at Leerink Partners 6th Annual Global Healthcare Conference 02/13/17

Read more

Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors 02/10/17

Read more


LEERINK Partners 6th Annual Global Healthcare Conference02/15/17 2:30 p.m. ETView eventSeattle Genetics Business Update02/10/17 8:30 a.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources